Dong Thap Participates in Research on Drugs for Controlled Treatment of Covid-19 Patients
In the morning of September 16th, Vice Chairman of the Provincial People's Committee (PPC)/ Deputy Head of the Provincial Steering Committee for Covid-19 Prevention and Control – Mr. Doan Tan Buu directly visited to check the implementation of antiviral drug Molnupiravir for controlled treatment of COVID-19 patients at the isolation area of student dormitory in Hoa Thuan ward, Cao Lanh city.
Vice Chairman of PPC - Mr. Doan Tan Buu inspecting the medicine packages
before deploying treatment for Covid-19 patients
Vice Chairman of PPC – Mr. Doan Tan Buu asked the medical force and doctors to carefully screen and select patients before using drugs; at the same time, must closely monitor their health situation while implementing controlled treatment. In case of abnormality symptoms, it must be reported immediately for timely handling; closely coordinate with the implementing units and take careful notes to have the most accurate report and evaluation of research results.
The research programme on using the antiviral drug molnupiravir for controlled treatment of COVID-19 patients with mild symptoms has been implemented in 02 provinces including Dong Thap and Kien Giang province by the Department of Science, Technology and Training of the Ministry of Health, Ho Chi Minh City University of Medicine and Pharmacy (technical support unit).
Specifically, patients participating in the programme are those who have been identified as mildly positive with SARS-CoV-2 such as fever, dry cough, sore throat, nasal congestion, fatigue, headache, aches and pains, tongue numbness; no signs of pneumonia or hypoxia, respiratory rate less than or equal to 20 breaths per minute, SpO2 higher than or equal to 96% when the patient breathes. Patients aged 18-65 can take the drug orally. If patients agree, they need to be strictly followed commitments to participate in the intervention programme.
A medicine package is a five-day use programme for an F0, including 20 Molnupiravir pills. After 5 days, all patients will be assessed for negative rates for SARS-CoV-2 and the rate of disease not progressing to a more severe symptom. During a 14-day period, patients will be monitored for disease symptoms and side effects if available.
In Dong Thap, the program will be implemented for about 2.000 Covid-19 patients with mild symptoms, who are isolated and monitored in concentrated isolation areas in the province. Imexpharm Pharmaceutical Joint Stock Company is the focal point of Molnupiravir drug management.
Việt Tiến
Translated by Gia Vi
